Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, headquartered in Lexington, Massachusetts, is a wholly owned subsidiary of Novo Nordisk. This privately held company employs 151 individuals. Dicerna focuses on developing RNAi-based therapies targeting disease-causing genes. Utilizing proprietary technologies such as GalXC™ and GalXC-Plus™, they aim to address challenging medical conditions, particularly those affecting the liver, but expanding into other therapeutic areas. Their efforts encompass rare and prevalent diseases, driven by research collaborations with prominent pharmaceutical companies. Dicerna's approach leverages RNA interference technology to silence genes responsible for disease progression. Their GalXC platform has demonstrated potential in treating diseases currently difficult to manage with traditional therapies. Dicerna Pharmaceuticals can be contacted via their career website: novonordisk-us.com/careers/find-a-job.html.